Matches in SemOpenAlex for { <https://semopenalex.org/work/W2535297451> ?p ?o ?g. }
- W2535297451 endingPage "23861" @default.
- W2535297451 startingPage "23851" @default.
- W2535297451 abstract "To determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Patients who were 1 to 30 years of age with relapsed/refractory solid tumors (including CNS) were eligible. Patients received daily oral sirolimus and cyclophosphamide (25-50 mg/m2/dose) on days 1-21 and oral topotecan (0.8 mg/m2/dose) on days 1-14 in 28-day cycles. Sirolimus steady-state plasma trough concentrations of 3-7.9 ng/mL and 8-12.0 ng/mL were evaluated, with dose escalation based on a 3+3 phase 1 design. Biomarkers of angiogenesis were also evaluated.Twenty-one patients were treated (median age 18 years; range 9-30). Dose-limiting toxicities included myelosuppression, ALT elevation, stomatitis, and hypertriglyceridemia. The MTD was sirolimus with trough goal of 8-12.0 ng/mL; cyclophosphamide 25 mg/m2/dose; and topotecan 0.8 mg/m2/dose. No objective responses were observed. Four patients had prolonged stable disease > 4 cycles (range 4-12). Correlative biomarker analyses demonstrated reductions in thrombospondin-1 (p=0.043) and soluble vascular endothelial growth factor receptor-2 plasma concentrations at 21 days compared to baseline.The combination of oral sirolimus, topotecan, and cyclophosphamide was well tolerated and biomarker studies demonstrated modulation of angiogenic pathways with this regimen." @default.
- W2535297451 created "2016-10-28" @default.
- W2535297451 creator A5001066329 @default.
- W2535297451 creator A5009258641 @default.
- W2535297451 creator A5011524529 @default.
- W2535297451 creator A5017840054 @default.
- W2535297451 creator A5019887410 @default.
- W2535297451 creator A5033864412 @default.
- W2535297451 creator A5038112278 @default.
- W2535297451 creator A5062929622 @default.
- W2535297451 creator A5069053611 @default.
- W2535297451 creator A5082896068 @default.
- W2535297451 date "2016-10-25" @default.
- W2535297451 modified "2023-10-18" @default.
- W2535297451 title "Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors" @default.
- W2535297451 cites W1546035334 @default.
- W2535297451 cites W1918358697 @default.
- W2535297451 cites W1935226228 @default.
- W2535297451 cites W1964505940 @default.
- W2535297451 cites W1982231207 @default.
- W2535297451 cites W1985361959 @default.
- W2535297451 cites W1989206745 @default.
- W2535297451 cites W1999811576 @default.
- W2535297451 cites W2002140390 @default.
- W2535297451 cites W2003537331 @default.
- W2535297451 cites W2013883015 @default.
- W2535297451 cites W2018176790 @default.
- W2535297451 cites W2019607817 @default.
- W2535297451 cites W2026351725 @default.
- W2535297451 cites W2028197028 @default.
- W2535297451 cites W2038544543 @default.
- W2535297451 cites W2062845584 @default.
- W2535297451 cites W2065508488 @default.
- W2535297451 cites W2069434008 @default.
- W2535297451 cites W2070301701 @default.
- W2535297451 cites W2070550035 @default.
- W2535297451 cites W2096398040 @default.
- W2535297451 cites W2099595985 @default.
- W2535297451 cites W2102392974 @default.
- W2535297451 cites W2114441352 @default.
- W2535297451 cites W2120304148 @default.
- W2535297451 cites W2121190158 @default.
- W2535297451 cites W2122763483 @default.
- W2535297451 cites W2132730776 @default.
- W2535297451 cites W2141314162 @default.
- W2535297451 cites W2156145250 @default.
- W2535297451 cites W2161680149 @default.
- W2535297451 cites W2164458048 @default.
- W2535297451 cites W2169965478 @default.
- W2535297451 cites W2243095616 @default.
- W2535297451 cites W2306722857 @default.
- W2535297451 cites W2587226846 @default.
- W2535297451 doi "https://doi.org/10.18632/oncotarget.12904" @default.
- W2535297451 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5410349" @default.
- W2535297451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27793021" @default.
- W2535297451 hasPublicationYear "2016" @default.
- W2535297451 type Work @default.
- W2535297451 sameAs 2535297451 @default.
- W2535297451 citedByCount "13" @default.
- W2535297451 countsByYear W25352974512017 @default.
- W2535297451 countsByYear W25352974512018 @default.
- W2535297451 countsByYear W25352974512019 @default.
- W2535297451 countsByYear W25352974512020 @default.
- W2535297451 countsByYear W25352974512021 @default.
- W2535297451 countsByYear W25352974512022 @default.
- W2535297451 countsByYear W25352974512023 @default.
- W2535297451 crossrefType "journal-article" @default.
- W2535297451 hasAuthorship W2535297451A5001066329 @default.
- W2535297451 hasAuthorship W2535297451A5009258641 @default.
- W2535297451 hasAuthorship W2535297451A5011524529 @default.
- W2535297451 hasAuthorship W2535297451A5017840054 @default.
- W2535297451 hasAuthorship W2535297451A5019887410 @default.
- W2535297451 hasAuthorship W2535297451A5033864412 @default.
- W2535297451 hasAuthorship W2535297451A5038112278 @default.
- W2535297451 hasAuthorship W2535297451A5062929622 @default.
- W2535297451 hasAuthorship W2535297451A5069053611 @default.
- W2535297451 hasAuthorship W2535297451A5082896068 @default.
- W2535297451 hasBestOaLocation W25352974511 @default.
- W2535297451 hasConcept C111113717 @default.
- W2535297451 hasConcept C112705442 @default.
- W2535297451 hasConcept C126322002 @default.
- W2535297451 hasConcept C126894567 @default.
- W2535297451 hasConcept C143998085 @default.
- W2535297451 hasConcept C2776694085 @default.
- W2535297451 hasConcept C2776755627 @default.
- W2535297451 hasConcept C2777921159 @default.
- W2535297451 hasConcept C2781209748 @default.
- W2535297451 hasConcept C2908647359 @default.
- W2535297451 hasConcept C71924100 @default.
- W2535297451 hasConcept C90924648 @default.
- W2535297451 hasConcept C98274493 @default.
- W2535297451 hasConcept C99454951 @default.
- W2535297451 hasConceptScore W2535297451C111113717 @default.
- W2535297451 hasConceptScore W2535297451C112705442 @default.
- W2535297451 hasConceptScore W2535297451C126322002 @default.
- W2535297451 hasConceptScore W2535297451C126894567 @default.
- W2535297451 hasConceptScore W2535297451C143998085 @default.
- W2535297451 hasConceptScore W2535297451C2776694085 @default.